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Abstract
Background—The primary cause of morbidity and mortality in patients with cystic fibrosis (CF)
is progressive obstructive pulmonary disease due to chronic endobronchial infection, particularly
with Pseudomonas aeruginosa (Pa). Risk factors for and clinical impact of early Pa infection in
young CF patients are less well understood.
Purpose—The present studies are designed to evaluate risk factors and outcomes associated with
early Pa acquisition, and the benefits and harms of four anti-pseudomonal treatment regimens in
young CF patients initiated after the first Pa positive respiratory culture.
Methods—The Early Pseudomonas Infection Control (EPIC) program consists of two studies, a
randomized multicenter trial in CF patients ages 1–12 years at first isolation of Pa from a respiratory
culture, and a longitudinal cohort study enrolling Pa-negative patients. Using a factorial design, trial
participants are assigned for 18 months to either anti-pseudomonal treatment on a scheduled quarterly
basis (cycled therapy) or based on recovery of Pa from quarterly respiratory cultures (culture-based
therapy). The study drugs include inhaled tobramycin (300 mg BID) for 28 days, combined with
either oral ciprofloxacin (15–20 mg/kg BID) or oral placebo for 14 days. The primary endpoints of
the trial are the time to pulmonary exacerbation requiring IV antibiotics or hospitalization for
respiratory symptoms, and the proportion of patients with new Pa-positive respiratory cultures during
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the study. The broad goals of the observational study are to describe the risk factors and outcomes
associated with early acquisition of Pa. 306 patients were randomized in the clinical trial and 1,787
were enrolled in the cohort study.
Conclusions—These companion studies will provide valuable epidemiological and
microbiological information on early CF lung disease and Pa acquisition, and safety and clinical
efficacy data on anti-pseudomonal treatment strategies for early Pa infections in the airways of young
children with CF.
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Cystic fibrosis (CF), an autosomal recessive disease lacking a curative therapy, has a current
median survival of over 36 years, and affects approximately 25,000–30,000 individuals in the
United States and 70,000 people worldwide [1–3]. The primary cause of morbidity and
mortality in patients with CF is progressive obstructive pulmonary disease associated with
chronic Pseudomonas aeruginosa (Pa) endobronchial bacterial infection and an intense
neutrophil-dominated host inflammatory response [4,5]. Pa, a ubiquitous environmental
bacterium, is the most important pathogen in CF lung disease. Pa infection can begin very
early in life, and the prevalence of Pa in respiratory cultures increases with age, from 10–30%
at ages 0–5 years to 80% at ages ≥18 years [1]. Unlike established Pa infection, features of
early Pa infection, including susceptibility to antibiotics, non-mucoid phenotype, and low
bacterial density, appear to provide a “window of opportunity” during which time anti-
pseudomonal therapy may be effective in eradicating Pa [6–8]. Over time, the distinct
microenvironment in the CF airways allows selection of Pa uniquely adapted for chronic,
persistent infection. These organisms are mucoid, form biofilms, become increasingly
antibiotic-resistant, are present at high density, and are virtually impossible to eradicate.
Chronic Pa infection is clearly associated with poorer clinical outcomes among patients with
CF [9–12]. The risk factors for and clinical impact of early Pa infection are even less
understood, yet are of great import to clinicians caring for young patients with CF. Preliminary
data suggest a favorable effect of aggressive treatment at first isolation of Pa from respiratory
cultures, but data from large randomized trials are lacking [5,12–14].
Thus, we designed a randomized trial in children with CF to investigate the benefits and harms
of aggressive, early anti-pseudomonal interventions with the goal of delaying or preventing
chronic Pa infection and its clinical consequences. Companion to this clinical trial is the first
large, multicenter, longitudinal observational study of early lung disease in CF, which enrolled
young Pa-negative patients and clinical trial participants. The goal of the observational study
is to determine improved strategies for prevention and treatment of early Pa infection.
Study Overview
In order to assess the clinical and microbiologic efficacy of early anti-pseudomonal therapy,
and more thoroughly address issues of safety and antimicrobial resistance, the Early
Pseudomonas Infection Control multi-center clinical trial (EPIC-CT) and an observational
study (EPIC-OBS) target children with CF younger than 12 years of age.
The EPIC-OBS serves both as a freestanding epidemiologic study of risk factors associated
with early Pa airway infection, and as an adjunct to the EPIC-CT by providing pre-study data
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on risk factors potentially affecting response to the trial regimens and post-enrollment follow-
up for the clinical trial participants for up to five years (Figure 1).
The EPIC-CT was designed to allow the randomized controlled evaluation of early intervention
with inhaled and oral anti-pseudomonal therapy in young patients with CF at first isolation of
Pa from respiratory cultures. Participants meeting the eligibility criteria were offered the
opportunity to be enrolled in the clinical trial and initiate or continue simultaneous participation
in the observational study. The clinical trial assigned children to two different antimicrobial
treatment strategies: (1) Cycled antibiotic therapy, i.e., treatment provided in quarterly cycles
regardless of findings from respiratory cultures obtained quarterly, and (2) Antibiotic therapy
based upon cultures, i.e., treatment based on recovery of Pa from respiratory cultures obtained
at scheduled quarterly intervals throughout the 18-month study period (Figure 2).
To summarize, the overall objectives of the clinical trial are to compare the clinical and
microbiological efficacy and safety of cycled therapy versus culture-based therapy, initiated
at the time of early Pa infection of the respiratory tract and given over an 18-month study
period. Because a true placebo group receiving no anti-pseudomonal antibiotic therapy was
not feasible at the time of study initiation in 2004, clinical trial participants will be also
compared with two external controls, a concurrent cohort (derived from the EPIC
Observational study) that will allow the evaluation of the generalizability of the clinical trial
results, and a historical group that will allow the evaluation of low versus high intensity
exposure to antipseudomonal antibiotics. This historical group, derived from an existing patient
registry and covering a period ranging from 1997–1999, had significantly less exposure to
inhaled tobramycin prior to the commercial product’s (TOBI) FDA approval in 1998. Children
in the historical group will be matched 2:1 for age and gender to each EPIC-CT participant.
THE OBSERVATIONAL STUDY COMPONENT
Objectives and Aims of EPIC-OBS
The primary aim of EPIC-OBS is the identification of risk factors associated with early age at
first isolation of Pa from respiratory cultures and with the early emergence of mucoid and
antibiotic-resistant strains of Pa, in particular, modifiable exposures, such as environmental
tobacco smoke, breastfeeding and daycare. The EPIC-OBS also aims to describe the
longitudinal changes in clinical endpoints (e.g., lung function, growth, exacerbation frequency)
associated with initial acquisition of Pa, as well as changes in clinical endpoints associated
with emergence of mucoid Pa and antibiotic-resistant Pa. Among subjects not enrolled in the
clinical trial, the effect of type and length of anti-pseudomonal therapy on clinical endpoints,
subsequent Pa serology, Pa antimicrobial resistance, Pa genotype, and emergence of other
pathogens will be examined. The longitudinal relationships between anti-pseudomonal
serology, isolation of Pa from respiratory cultures, and evolving clinical signs and symptoms
during early CF lung disease will be described. Clinical outcomes associated with isolation of
Staphylococcus aureus (S. aureus) from respiratory cultures, and with emergence of
methicillin-resistant S. aureus (MRSA) will also be evaluated. DNA samples extracted from
whole blood are being collected and banked from participants and their parents of origin for a
separate planned evaluation of genetic factors that may be associated with CF pathogenesis,
disease progression, and clinical outcomes. Finally, Pa isolates and serum samples from
observational participants are banked for future studies to enhance the understanding of
microbiological aspects of early CF lung disease.
For subjects who enroll in the EPIC-CT, the observational study provides pre-enrollment data
to allow examination of the association between risk factors prior to trial enrollment,
particularly Pa serology and Pa phenotype (mucoid vs. non-mucoid), and response to trial
regimens. Moreover, the observational study provides follow-up data on trial endpoints after
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completion of trial participation to allow assessment of the long-term effects of trial regimens
(Figure 1). The observational study will also allow characterization of patients who declined
enrollment in the clinical trial to estimate the presence of potential selection bias and to evaluate
the effect of non-protocol based antimicrobial approaches on the clinical, microbiology, and
serology endpoints of interest in the clinical trial.
Study Design of EPIC-OBS
The EPIC-OBS is an ongoing prospective, observational cohort study. The size of the original
cohort was 1,787 participants at 59 CF centers. CF patients ≤12 years of age at the time of
enrollment were eligible if they had no prior isolation of Pa from respiratory cultures, or if
prior history of isolation of Pa from respiratory cultures, at least a two-year period with Pa
negative cultures (documented by at least 1 culture annually) or were concurrently enrolled in
the EPIC-CT. The study was approved by the Institutional Review Board at each participating
site, and all participants or their surrogates provided written informed consent.
The EPIC-OBS involves prospective data and specimen collection (Table 1). Clinical care and
monitoring is not affected by study participation. The Cystic Fibrosis Foundation (CFF)
maintains a National Patient Registry containing a wide array of demographic, clinical, and
actuarial data on all patients seen at CF care centers. Registry data entry is encounter-based
and submitted via a secure web site (www.portcf.org). The EPIC-OBS study is made possible
by the existence of this resource: data collection occurs at each encounter and via an annual
family survey utilizing an augmented version of the CFF Registry containing the standard
Registry data collection forms as well as additional, study-specific forms. The EPIC-OBS
annual family survey is a parent/family questionnaire on potential risk factors for Pa
acquisition, such as environmental tobacco smoke and daycare attendance. Study sites are also
queried annually regarding issues such as infection control practices and use of standardized
monitoring and treatment regimens in young CF patients.
EPIC-OBS participants have a serum sample collected annually for evaluation of Pa serology
and for banking. After the first isolation of Pa from respiratory culture at the local site
laboratory, an annual respiratory specimen is sent to the Coordinating Center Core
Microbiology Laboratory for semi-quantitative culture, evaluation of Pa mucoidy and banking.
If available, initial Pa isolates from the local site laboratory are also shipped to the Core
Microbiology Laboratory for banking. A single whole blood sample is collected from
participants and a whole blood sample or buccal swab is collected from parents of origin for
DNA extraction and banking.
Sample Size and Power for EPIC-OBS
The sample size, number of sites for both the EPIC-OBS and EPIC-CT, and duration of
enrollment were determined based on statistics from the 2000 CFF National Patient Registry
[1] and questionnaire data from prospective sites participating in the EPIC studies. Combining
the information from both sources indicated that at approximately 60 sites, a sample of about
2,000 total Pa negative patients age 12 and younger was available. The sample size justification
was based on the primary EPIC-OBS aim, i.e., to define risk factors for early age at first
isolation of Pa. We hypothesized that environmental tobacco smoke exposure and other
modifiable exposures would have an effect on age at first isolation of Pa at least as great as
that of other known risk factors evaluated in prior studies, such as aerosol use, mother’s
education, and delta F508 homozygous status [15,16]. The prevalence of smoking among
parents of children with CF ranges from 15 to 40% nationally. The minimum detectable hazard
ratios, varying the underlying prevalence of the risk factor from 0.2 to 0.5, and as a function
of study power, ranged from 1.32 to 1.25 for a power of 0.8. These detectable hazard ratios are
within the range of risk estimates reported in prior studies. All calculations were based on the
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log-rank statistic, assumed a two-sided .05 significance level and the occurrence of 650 events
(conversions to Pa positive status during the study period) and uniform accrual of the study
participants over the two year enrollment period.
Table 2 provides the projected number of patients converting to Pa-positive during the study
period. The following assumptions were made to estimate duration of enrollment in EPIC-OBS
at the participating sites: 1. An enrollment rate of 70% of eligible patients; 2. 15% annual rate
of conversion to Pa-positive; 3. 40% of Pa positive patients would enroll in EPIC-CT; and 4.
10% of enrolled subjects would drop-out or be lost to follow-up by the end of the study. Based
on these assumptions, enrollment into the EPIC-OBS was needed for the first two years of the
study to achieve a sample of approximately 1,400 Pa negative patients, of whom 650
participants were expected to convert to Pa positive before completion of the observation
period, from which approximately 300 were expected to enroll in the EPIC-CT. Enrollment
rates exceeded expectations, and the observational study actually enrolled 1,787 rather than
1,400 participants.
THE CLINICAL TRIAL COMPONENT
Objectives of EPIC-CT
The primary objectives of the clinical trial are to investigate if an intensive quarterly anti-
pseudomonal strategy (cycled therapy) reduces pulmonary exacerbations and the isolation of
Pa from respiratory cultures, compared with a strategy of anti-pseudomonal administration
solely based upon recovery of positive respiratory cultures collected quarterly (culture-based
therapy). The specific primary aim is twofold and includes a clinical and a microbiological
endpoint. The clinical endpoint is the time to first pulmonary exacerbation (Table 3) requiring
intravenous antibiotics or hospital admission during the 18 month study period. The
microbiological endpoint is the proportion of Pa-positive respiratory cultures among quarterly
cultures obtained after randomization. Secondary independent clinical efficacy endpoints
include: (1) time to pulmonary exacerbation not requiring intravenous antibiotic usage or
hospitalization, (2) frequencies of pulmonary exacerbations, hospitalizations, and use of
concomitant oral, inhaled, and intravenous antibiotics, (4) anthropometric measures (linear
growth, weight gain), (5) pulmonary function tests including FVC, FEF25%–75%, and FEV1
(patients 4 years of age and older, able to reproducibly perform spirometry), and (6) total
hospitalization days. Secondary microbiological endpoints include the microbiologic profile
of Pa isolates from respiratory cultures as indicated by: (1) changes in antibiotic susceptibility
patterns (minimal inhibitory concentrations of 12 antibiotics), (2) colony morphology, and (3)
the presence of mucoid isolates from baseline to the end of the study. The emergence of
intrinsically aminoglycoside- and ciprofloxacin-resistant non-pseudomonal organisms is also
evaluated (e.g., B. cepacia, A. xylosoxidans, and S. maltophilia).
Study participants are also followed with respect to the serologic response against selected
Pa surface and secretory antigens and changes in inflammatory markers (white blood count
with differential and C reactive protein).
The comparison of the safety profiles between the two groups include the emergence of organ
toxicities detected by serial evaluation of articular/skeletal symptoms, renal function, hearing
acuity, liver function, hematological profile, and adverse events.
Choice of Interventions in the EPIC-CT
In young patients in whom Pa is isolated for the first time, the goal of treatment is maintaining
sustained eradication rather than controlling a chronic infection. The main considerations that
were taken into account in the treatment selection process were the following: (1) a group
receiving no active anti-pseudomonal antibiotics was not deemed feasible in consideration of
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current clinical practice, (2) 28-day therapy seemed appropriate based on previous literature
concerning cycled inhaled tobramycin [5,17], and (3) a quarterly cycle would allow sufficient
time off antibiotics to limit exposure to antimicrobials.
The proposed regimens were discussed among a panel of experts from the CF community
convened by the study principal investigators and the CFF to develop the optimal range of
therapeutic approaches that would ensure adequate microbial coverage for all subjects and
preserve clinical equipoise in the CF community.
A systematic review of the literature was prepared for the panel to assist in selection of the
most effective and safest anti-pseudomonal agents for administration in this young age group.
Aminoglycosides are the drug class with the largest amount of information available about
sputum-antibiotic interactions in patients with CF. It was the general agreement that
tobramycin for inhalation was a logical prototypical agent for trials of early intervention in CF,
as its safety and efficacy in patients six years and older is the most thoroughly documented of
all inhaled antibiotics. It is the only FDA approved inhaled antibiotic for the treatment of Pa
infection in patients with CF. There have been several studies in children less than six years
old demonstrating at least transient Pa eradication from upper and/or lower airways with
inhaled tobramycin [5,12,18,19].
The recommended dosage of preservative-free inhaled tobramycin for adults and children ≥6
years of age is 300 mg. This dose was demonstrated to attain sputum levels adequate to
overcome potential sputum antagonism [17]. Inhaled tobramycin has also been shown to be
safe and to achieve therapeutic concentrations in the lower airway of patients <6 years of age
[20]. Dose adjustments for age or weight are not required.
Studies in patients chronically colonized with Pa support the use of inhaled tobramycin twice
a day for cycles of 28 days receiving drug, followed by 1 month not receiving drug. In colonized
patients, data suggested that the effect of a 28-day cycle persists at least 56 days in over half
of the patients, indicating that a 28-day cycle followed by 56 days off therapy may be
appropriate [5]. This discontinuous dosing has the theoretical advantages of minimizing
emergence of resistance and of reducing drug exposure. Therefore, quarterly therapy was
selected for this young population.
The consensus panel supported a combination of an inhaled antibiotic with an oral
fluoroquinolone such as ciprofloxacin for initial eradication. There are several presumed
advantages to this approach. First, oral fluoroquinolones are distributed systemically providing
access to the sinuses and upper airway, a potential reservoir for re-infection [21]. Second, they
are bactericidal agents which have a broad spectrum of antimicrobial activity with excellent
in vitro activity against Pa strains from CF patients [22] and documented in vitro synergism
with tobramycin [23]. Third, they are well tolerated and easily administered. Fourth, the risk
of emergence of resistance can be minimized by short-term administration [24]. The
pharmacokinetic profile of oral and intravenous ciprofloxacin was examined in 150 pediatric
patients ages 0.3–17 years, including 28 children with CF. On average, the most frequently
used dose of ciprofloxacin in children is twice daily 15–20 mg/kg/dose up to a maximum of
750 mg/dose, for a two-week course [25].
Study Design
This clinical trial is a multicenter, randomized study of young children with CF. Fifty seven
clinical centers throughout the US participated and the enrollment goal of 300 participants was
met in 2.5 years (Figure 2). Participating sites are listed in the Appendix. All participating
centers obtained IRB approval from their respective institutions. After obtaining informed
consent/assent, 306 participants have been equally randomized to one of two early anti-
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pseudomonal treatment algorithms (cycled or culture-based therapy groups). The duration of
study participation for each subject is 18 months, during which time each participant receives
up to six treatment cycles. In combination with inhaled tobramycin (Novartis Pharmaceutical
Corp), patients were randomized to receive either oral ciprofloxacin or oral placebo (Bayer
Healthcare AG).
Randomization was carried out by permuted blocks, and performed using a computer generated
sequence. The randomization blocks did not account for clinical site since we assumed that the
potential clustering effect of clinical site would be mitigated by the large number of sites (i.e.,
large number of clusters of small size).
At study enrollment, participants received an initial course of anti-pseudomonal antibiotic
therapy consisting of 28 days of inhaled tobramycin with 14 days of oral ciprofloxacin or
placebo. To promote initial eradication of Pa at the beginning of the study, participants
randomized to any of the study groups could receive an additional 28-day course of inhaled
tobramycin at the end of the first treatment cycle if their respiratory cultures sampled after
three weeks of the first anti-pseudomonal cycle continued to be positive for Pa. They did not
receive a second course of ciprofloxacin or placebo.
Following this initial antibiotic regimen, participants randomized to the cycled therapy group
(n=153) received therapy administrated in quarterly cycles for five additional quarters, while
participants randomized to the culture-based therapy group (n=153) received a course of
therapy only when quarterly respiratory cultures, from either the central or the local laboratory,
were found positive for Pa for the same study duration. The same anti-pseudomonal antibiotics,
inhaled tobramycin twice-daily for 28 days and oral ciprofloxacin or placebo twice-daily for
14 days, were used in both groups. The inhaled tobramycin therapy was not blinded. The
ciprofloxacin was administered as a pill to older children taking 250 mg or higher dose and
placebo tablets were provided by Bayer. Younger children received ciprofloxacin suspension
or taste masked placebo suspension provided by Bayer.
Overall, the study follows a factorial design and participants were allocated to the treatment
regimens as displayed in Figure 2. Once patients were assigned to a treatment group, patients
and treating physicians had to adhere to the assigned regimen for the 18-month study period.
Except for the initial two study visits, patients were seen on a quarterly basis in conjunction
with their routine clinic visits. Irrespective of randomization assignment, participants in each
of these groups were allowed to receive necessary antibiotic therapy for treatment of a
pulmonary exacerbation in addition to their assigned treatment regimen. An operational
definition of pulmonary exacerbation was developed for the purpose of the study (Table 3).
Participants presenting in a stable condition at the time of randomization were assigned to one
of the study regimens immediately. Study participants presenting with new onset of a
pulmonary exacerbation requiring IV antibiotics or hospital admission were treated at the
discretion of the investigator and then randomized at the following quarter if they continued
to meet the study eligibility criteria.
Blinding
Inhaled tobramycin was provided in an open label fashion, while oral ciprofloxacin was
provided in a double-blinded fashion. To minimize potential bias due to the lack of blinding,
we developed an objective and rigorous operational definition of pulmonary exacerbation
(Table 3) and we verified all the hospitalization records to ensure that the reason of
hospitalization was a pulmonary exacerbation. A patient diary was maintained as a
corroborating mechanism to ensure the active reporting of any and all respiratory symptoms.
A review committee is devoted to the quality control of this endpoint in a blinded fashion.
Further, all of the secondary endpoints are objective measures. Additional measures to
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minimize bias included an extensive ongoing training of both physicians and research
coordinators by quarterly newsletters, teleconferences and annual study meetings. Educational
tools for families and primary care physicians who might also be involved in the care of the
study participants have also been provided. All protocol deviations and violations have been
evaluated on a case-by-case basis.
Choice of Study Population
Male and female subjects ≥1 year and ≤12 years of age with a diagnosis of CF with a
documented new onset of oropharyngeal, sputum or lower respiratory tract culture positive for
Pa within six months prior to study entry were eligible for participation in this study. For study
purposes, first isolation of Pa was defined as the first lifetime documented respiratory culture
positive for Pa or as a positive Pa culture after at least two-year absence of Pa growth
(minimum of one documented negative Pa culture per year). For participants ages 12 to 15
months, at least one Pa positive respiratory culture since birth was required. Children below
the age of 1 year were not considered for enrollment because oral ciprofloxacin could not be
administered for safety concerns regarding potential arthropathy [26,27]. Other eligibility
criteria included: Diagnosis of CF [28,29]; Clinically stable with no evidence of any significant
respiratory symptoms at screening that would require administration of intravenous
antipseudomonal antibiotics, oxygen supplementation and/or hospitalization; Signed informed
consent by parent or legal guardian.
Patients were excluded from the study if they had a history of aminoglycoside hypersensitivity
or adverse reaction to inhaled aminoglycoside, history of hypersensitivity or adverse event
associated with ciprofloxacin or other fluoroquinolones, abnormal renal function (serum
creatinine >1.5 times the upper limit of normal for age), clinically documented chronic hearing
loss, serum transaminase levels at the screening visit >2 times the upper limit of normal range,
administration of any investigational drug within 30 days prior to enrollment, chronic
administration of loop diuretics, administration of theophylline or other methyl-xanthines
within 30 days of the time of enrollment, administration of more than one course of intravenous
anti-pseudomonal antibiotics (defined as at least 10 days of therapy) in the 2 years prior to
baseline or more than one course (at least 28 continuous days of therapy) of inhaled anti-
pseudomonal antibiotics within two years prior to study entry, and chronic macrolides use
(more than 3-month duration) within 3 months of baseline; presence of a condition or
abnormality that in the opinion of the Investigator would compromise the safety of the patient
or the quality of the data. Intravenous or inhaled anti-pseudomonal antibiotics needed to be
completed more than 30 days prior to baseline.
Study Subject Screening and Follow up Strategies
Potential study participants were screened at the participating sites whether or not they were
previously enrolled in the observational study. Patients meeting the criteria for the EPIC-CT
were enrolled and randomization assignment was made centrally via an interactive voice
response system. Table 4 shows the content of the baseline encounter and subsequent quarterly
study visits for the 18 month study duration. Patients had microbiology samples from
oropharyngeal swab cultures at every quarterly visit. Anthropometric measures and nutritional
assessment included length (children ≤18 months) or height, and weight. Spirometry data were
collected in subjects 4 years of age or older, according to the guidelines stipulated in the 1994
American Thoracic Society Guidelines [30], with modified criteria for children [31].
EPIC-CT participants, who were not previously enrolled in the observational study, had the
option to enroll in EPIC-OBS prior to completion of the clinical trial in order to collect long-
term clinical and safety follow-up data.
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Due to potential for aminoglycoside ototoxicity, audiometry utilizing age appropriate testing
[32,33] with tympanometry to detect the presence of fluid in the middle ear was performed at
study enrollment, at the end of the first year and at study completion. Abnormal hearing was
defined as an auditory threshold ≥25 dB at any frequency (500–8000 Hz) in either ear. If
abnormal results were found during the study period, confirmatory audiometry was repeated
four weeks later. Children with abnormal audiologic findings had a tympanometry performed,
and if both were abnormal, they were referred to the study investigator or medically-qualified
sub-investigator for an ear examination. Audiometry was not collected on all participants
because some sites did not have the capability to perform audiometric testing in this age group
and some children were unable to comply with the testing procedure or had uninterpretable
results due to pneumatic equalizing tube placement.
Blood samples were obtained for assessment of clinical status and included blood chemistry
(creatinine, blood urea nitrogen, and liver function tests including hepatic transaminases [AST
and ALT] and γGT, and C reactive protein), and a complete blood count (hemoglobin,
hematocrit, red blood cell count, white blood cell count, and white blood cell differential count).
After baseline, blood samples were obtained twice a year and at the end of the study. Blood
sampling also included serum banking for Pa serology assays. For this purpose, the blood
sample was centrifuged, the serum extracted, and the specimen stored at −70°C.
Chronic use of azithromycin was not permitted. All participants were encouraged to remain
on the same medications throughout the entire study period, as medically feasible. Study
participants maintained a diary while on the study and the information recorded in the patient
diary was abstracted at every clinic visit. The diary collected data among others on treatment
adherence and changes in concomitant medications.
Drug Distribution and Adherence to Treatment Regimen
Within seven days of the study visit participants were contacted to report the microbiology
results and to review the treatment plan. If participants required study medication based on
group assignment, the drug was prescribed at this time. Study drugs (tobramycin solution for
inhalation, ciprofloxacin suspension or tablets, or a matched oral placebo) were distributed by
a central pharmacy and mailed to the study participants’ domicile within 48 hours of
prescription. At the first treatment cycle patients were also provided with a nebulizer (PARI-
Proneb® Ultra compressors and PARI LC Plus® reusable nebulizers, PARI Respiratory
Equipment Inc., Midlothian, VA). Participants were contacted within 48 hours of prescription
of the study drugs to verify drug receipt, and were instructed to initiate treatment upon receipt
of the study drugs. Subsequently, participants were contacted within 14 days of the clinic visit
to identify occurrence of adverse events including a musculoskeletal assessment survey, and
to discuss study medication adherence. All participants were again contacted within 6 weeks
of the clinic visit to evaluate possible changes in health status.
Further monitoring for patient adherence to prescribed treatment regimen (cycled and culture-
based treatment arms) consisted of parent recall at quarterly visits and review of parent diary.
The diary collected data on daily drug consumption, any changes in patient health or new onset
of symptoms, medication use, and encounters with other health-care providers. The diary was
maintained to ensure, among other things, an active mechanism to capture the possible
occurrence of new respiratory symptoms that could qualify as a study defined pulmonary
exacerbation.
Microbiology Methods and Specimen Collection
Oropharyngeal specimens were obtained at all study visits. Specimens were collected with a
cotton-tipped swab from the posterior oropharyngeal wall and tonsillar pillars. Participants
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were encouraged to cough prior to collection of the OP specimen. With the exception of the
specimen obtained at the end of the first treatment cycle (which was processed at the site
laboratory), all specimens were processed at the core microbiology laboratory at Children’s
Hospital and Regional Medical Center in Seattle, WA. Oropharyngeal swab specimens were
sent on wet ice by overnight express shipment to the core microbiology laboratory, and needed
to be received and cultured within 2 calendar days of collection. Bacterial culture techniques
were performed according to core microbiology laboratory standard procedures using a semi-
quantitative bacterial culture technique [34,35]. All organisms were identified using standard
techniques, including standard biochemical testing and PCR techniques [36]. All Pa isolates
were assessed for mucoid phenotype. Minimal inhibitory concentrations (MIC) for Pa of 12
antibiotics were determined using a semi-automated microbroth dilution (Sensititre, AccuMed,
Westlake, OH), according to standard National Committee on Clinical Laboratory Standards
methods. MICs for any Pa isolate were performed at baseline and every six months.
We conducted quality control procedures to ensure that the sample shipment and processing
methods would yield accurate results. For this purpose we spiked 50 samples with inoculums
of known micro-organism species (Pa, Stenotrophomonas maltophilia, Achromobacter
xylosoxidans, and “no organism”) and density (103 to 105 CFU) that were sent blindly to the
core microbiology laboratory. The specificity for Pa identification was excellent (100%), as
there were no instances of Pa mis-identification. There was a single instance of the laboratory
finding no isolates from a Pa positive sample, yielding a sensitivity for Pa isolation of 97%.
To further evaluate measurement error due to sampling, manipulation, and transport, data were
collected from the clinical site microbiology laboratory to evaluate concordance between
results for those participants who had two simultaneous or sequential oropharyngeal cultures
collected at the same study visit.
Sample Size and Power of EPIC-CT
By design, the primary study endpoint for which the study is powered is the clinical efficacy
endpoint, time to first exacerbation requiring intravenous antibiotics and/or hospitalization,
which will be compared between treatment groups using a hazard ratio as an estimate of the
relative risk. The primary analysis will compare the more aggressive treatment group, cycled
therapy, to the less aggressive treatment group, culture-based therapy to evaluate the relative
reduction in pulmonary exacerbations achieved by the more aggressive therapy. To determine
the statistical power and sample size for this clinical efficacy endpoint, we first obtained
expected rates of exacerbation in this patient population.
To determine a reasonable relative risk size for which to power this clinical efficacy endpoint,
we estimated the annual exacerbation event rate using data on over 40,000 person-years
represented in the CFF National Patient Registry during 1985–2000 [37]. All patients born in
1985 or later and who were between the ages of 1 and 12 were classified into three mutually
exclusive groups at each calendar year: (i) patients with no positive Pa culture since birth; (ii)
patients who had the first positive culture during that year, and (iii) patients with at least one
positive culture in previous years. Based on the percentages of patients experiencing at least
one exacerbation related event during a calendar year, we estimated that the annual incidence
rate of exacerbations was 0.17 in group (i), 0.36 in group (ii), and 0.37 in group (iii). These
rates appeared to be consistent across age categories within each group. We assumed that an
aggressive early antibiotic therapy could potentially reduce the risk of exacerbation by as much
as 50% when comparing group (ii) to group (i). Based on the annual exacerbation incidence
rates estimated in the registry, an 18-month study with 300 patients had 80% power to detect
a relative risk of approximately 0.6 or lower, equivalent to detecting a 40% or greater reduction
in risk of pulmonary exacerbations. The primary microbiologic analysis of the proportion of
Pa positive cultures in the 18-month study period will also compare the cycled therapy arm to
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the culture-based therapy arm. For this objective, a sample size of 300 subjects provides 80%
power to detect an odds ratio 0.6 or smaller for Pa-positive respiratory cultures between the
two treatment strategies.
Factorial Aspects of Sample Size and Power
The design of this study makes it possible to perform separate evaluations of (1) the effect of
two different tobramycin treatment strategies and (2) the effect of oral ciprofloxacin versus
oral placebo, each based on comparing two groups of 150 study participants. The first
evaluation would compare the cycled versus the culture-based group, and the second evaluation
would compare the group assigned to receive oral ciprofloxacin (regardless of tobramycin
regimen) with the group assigned to receive oral placebo. The secondary analysis will explore
the main effect of ciprofloxacin by comparing all participants randomized to oral ciprofloxacin
to all participants randomized to placebo. Since the sample size in each of these groups is the
same as for the primary comparison, the study will have the same power for this analysis as
the primary analysis. Assuming lack of interaction between cycled therapy and ciprofloxacin,
the factorial structure of the study will allow performing two independent comparisons with
adequate power, by spending only one degree of freedom on each comparison. The study would
have reduced power for finding an effect if there is a negative interaction between cycled
therapy and ciprofloxacin which is thought to be unlikely. However, we could also gain power
if there was a positive synergistic effect between the cycled therapy and ciprofloxacin.
Importantly, further exploratory analyses will be performed to investigate potential interactions
between the tobramycin and ciprofloxacin regimens. These analyses will involve comparing
smaller subgroups of participants in each of the four relevant subgroups (approximately 75
participants per group).
A modified intent-to-treat (ITT) population was defined as all randomized participants who
received at least one dose of study drug.
Statistical analysis plan
By design, the primary study endpoint for which the study is powered is the clinical efficacy
endpoint, time to first protocol-defined pulmonary exacerbation requiring intravenous
antibiotics and/or hospitalization. The censored failure time will be taken as the diagnosis date
of the pulmonary exacerbation, or the end of follow-up if no exacerbation meeting these criteria
has occurred. End of follow-up is defined as the date of the last study visit completed by the
participant. Time will be measured in number of days post Day 0, the first day study therapy
was started. The null hypothesis is that there is no difference between the cycled therapy and
culture-based therapy groups in terms of the time to first protocol-defined exacerbation
requiring intravenous antibiotics and/or hospitalization.
A Kaplan-Meier plot will be used to graphically display estimates of the survivor function in
terms of the proportion of participants who were exacerbation free over time for both the cycled
and culture-based groups. Relative risk due to treatment will be estimated using a Cox
proportional hazards regression model, with covariate adjustment for baseline age group (1–
3, >3–6, and >6 years). The significance of the treatment group variable will be tested by the
likelihood ratio test at a two-sided 0.05 level of significance. The relative risk due to treatment
from this model and corresponding 95% confidence interval will be the primary measure of
treatment effect. Secondary analyses will evaluate the interaction between the inhaled and oral
treatment groups within the context of this model, and similar models will be used to investigate
differences between treatment groups with respect to an important secondary endpoint, time
to pulmonary exacerbation requiring any antibiotics (inhaled, oral, or IV) and/or
hospitalization. The following covariates will be considered for adjustment in exploratory
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models for these endpoints: gender, enrollment season, Pa status at enrollment, and/or
geographic region.
The microbiology endpoint is the proportion of Pa-positive respiratory cultures among the
seven respiratory cultures taken during the 18 months of the follow-up. The respiratory culture
results obtained from oropharyngeal cultures or expectorated sputum cultures obtained at
weeks 3, 10, 22, 34, 46, 58, and 70 will be used in this analysis. The response will be binary
(positive or negative culture). In the rare event that both an oropharyngeal culture and an
expectorated sputum culture are available at a given visit and produce discordant results, a
positive result will be used in the analysis for this visit. The ITT population will be used for
this longitudinal analysis and missing data will not be included. A generalized estimating
equation (GEE) model using a logit link will be used to model this data with an independence
working correlation matrix. The significance of the treatment group variable will be tested by
the Wald test using a two-sided 0.05 level of significance. The treatment associated odds ratio
from this model and corresponding 95% confidence interval will be the primary measure of
treatment effect. The estimated treatment effect will be interpreted as the marginal odds ratio
of Pa-positive respiratory cultures during the 18 months.
Sensitivity analyses will be performed in order to evaluate the robustness of the primary
microbiologic results to missing culture data, which by virtue of study design should be
minimal. Specifically, we will perform three additional analyses for the primary microbiologic
endpoint: (1) an analysis which imputes missing respiratory culture data using the Last
Observation Carried Forward (LOCF) method, (2) an analysis which assumes all missing
culture data is negative for Pa, and (3) an analysis which assumes all missing culture data is
positive for Pa. A further analysis will investigate the sensitivity of the results to the
augmentation of core laboratory results with available results from individual site microbiology
laboratories. In some instances, participants were double-swabbed and one swab was sent to
the core lab and one to the site lab. In instances for which the site lab result was positive for
Pa and the core lab was negative, the final result will be treated as positive. Additional
secondary endpoints including longitudinal changes in anthropometric measures and
spirometry will be modeled using the GEE framework to test for differences in the 18-month
change in each endpoint. Adverse events will be descriptively summarized by MEDRA system
organ class and preferred term. Colony morphology will be summarized by the eradication and
incidence patterns during the follow up period as compared to baseline for each of the following
bacterial organisms: P. aeruginosa, A. xylosoxidan, B. cepacia, S. aureus and S. maltophilia.
This analysis will primarily be descriptive, and the proportion of patients who have eradicated
or newly acquired the organism by the end of the study will be summarized with corresponding
95% confidence intervals.
Adverse event monitoring
In the case of a serious adverse event (as defined by the FDA 21 CFR 312.32) the site
investigator notifies the Coordinating Center within 24 hours of learning of the event.
Each adverse event is entered into the case report form and evaluated with respect to intensity,
seriousness, causality (relationship to treatment) and actions taken. A summary of potential
trends or unexpected events is provided to the Data Safety Monitoring Board for further review
and evaluation.
Data and Safety Monitoring Board (DSMB)
Safety is monitored on an ongoing basis throughout the trial by a Data and Safety Monitoring
Board (DSMB) appointed by the National Heart Lung and Blood Institute (NHLBI). The
DSMB convenes at fixed times during the study in open and closed meetings at approximately
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6 month intervals, including an annual in-person meeting. At each meeting, the DSMB reviews
safety data, enrollment data, protocol violations, and overall study progress. Descriptions of
serious adverse events are communicated to the DSMB Chair within 24 hours of their
occurrence.
There are no pre-specified stopping rules for efficacy or futility. If the data from this study are
unable to support the superiority of the cycled based treatment regimen to the culture based
therapy in terms of both clinical and microbiologic efficacy, this would be an important result
that could influence clinical care. In particular, there would be no supportive data to suggest
that newly colonized CF patients be aggressively treated regardless of their culture positivity.
If the two regimens are equal in terms of efficacy, the secondary endpoints regarding safety
and microbiologic resistance become even more important for determining which regimen is
superior and these must be evaluated for the entire duration of the study. The DSMB follows
the safety (quarterly) and efficacy (semi-annually) endpoints on a regular basis and could stop
the study at any time if they felt it was ethically necessary.
Study enrollment
During the 2.5 years enrollment period, from December 20, 2004 to February 7, 2008, the
actual accrual was excellent due to excellent participation by all sites, closely overlapping the
projected figures (Figure 3). Clinical site performance is monitored on an ongoing basis and,
if deficiencies are identified, these are addressed in a timely fashion.
DISCUSSION
The major objective of EPIC-CT is to help define a safe, effective and systematic approach to
the treatment of first isolation of Pa from young CF patients. These young patients potentially
have the most to gain from aggressive early intervention, but also the most to lose in terms of
cumulative drug toxicities and acquisition of resistant pathogens. If the study demonstrates
both a microbiologic effect and clinical efficacy of aggressive therapy without significant
adverse events or high rates of acquisition of resistant organisms, then there would be a strong
rationale for aggressive early intervention. If the two treatment approaches are not different
then the use of aggressive cycled antibiotic therapy must be reassessed.
The major objectives of the EPIC-OBS study are 1) to provide a closely-monitored cohort of
young children prior to potential EPIC-CT entry, 2) to provide long-term follow-up of the
treatment regimens for the subset of randomized patients, and 3) to establish a large, multi-
center, well-characterized cohort of young children with CF to obtain more generalizable data
on the risk factors for and impact of Pa acquisition and infection. The ultimate goal is for this
cohort to be closely monitored for at least 10 years with both study-specific data collection and
ongoing use of the CF Patient Registry. We anticipate that this longitudinal study will be
informative on both risks factors for and clinical outcomes of initial, chronic, and mucoid Pa
infection, and will explore the impact of polymicrobial infections (interaction of S. aureus and
Pa) in children with CF. The banked serum will provide a rich resource for the analyses of
serologic markers of early and chronic Pa infection, and other potential biomarkers of early
CF lung disease. The DNA bank from whole blood of EPIC-OBS participants will provide a
unique resource for the evaluation of genetic modifiers of early CF disease.
This initiative represents the largest cohort and therapeutic study ever conducted in children
with CF and provides a model of how to conduct a phase 3 trial in a population of young
children. The project was made possible under the auspices of the Cystic Fibrosis Foundation
and the National Heart, Lung and Blood Institute who joined forces to create a cooperative
program, along with the support of industry who donated study drugs and supplies. The studies
made use of existing resources both during the planning and implementation phase as provided
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by the linkage to the National CFF Registry. Similar to the design of the Women’s Health
Initiative [38] that combined a cohort study and a clinical trial, the observational cohort study
not only serves as a free-standing epidemiologic study of early CF lung disease, but also
provides a pool of potential clinical trial participants and provides long term follow-up data on
clinical trial participants. These features should provide an ideal setting for the interpretation
of the clinical trial findings and their generalizability. A large number of sites were recruited
to ensure timely enrollment and provide a broad geographic distribution and to ensure the
inclusion of a representative sample of the population.
In the trial planning stage, a consensus process among experts in the CF field was used to
ensure that the study treatment strategies were optimal in terms of administration schedule,
dosing, safety, and efficacy in this young population. A site survey was also distributed to
confirm that the proposed strategies were acceptable in the context of the local practices and
in equipoise with current treatments in use at each participating institution. This process
ensured that the proposed strategies would be well accepted by the CF community and
facilitated successful enrollment throughout the study period.
In an effort to minimize the burden of a long term trial on participants and their families, we
scheduled the clinical trial study visits to coincide with routine clinic visits and study drugs
were shipped directly to the participant’s residence. Because of frequent microbiology
sampling, the study also avoided the use of invasive sampling procedures and ensured that
sampling occurred in conjunction with procedures performed (blood draws and oropharyngeal
swabs) for routine care. Although Pa monitoring via oropharyngeal cultures is suboptimal,
more invasive approaches were not feasible in a study of this size and in the age range of the
study participants. Results of study oropharyngeal cultures were provided to the sites to allow
continued clinical care.
This study did not examine patient/family reported outcomes due to the lack of availability of
validated instruments for participants of ages 6 years or younger [39]. Future studies should
consider collecting age-appropriate quality of life measures to evaluate the effect of long term
interventions on treatment burden and health related quality of life.
The emphasis placed on engaging the clinical sites in the early phase of study development
and designing the study to meet the needs of both the sites and the participant’s families likely
contributed to the excellent enrollment rate that exceeded projections by 6 months. In addition,
the attrition rate has remained at less than 10% easily meeting expectations.
In conclusion, this study will provide valuable clinical and microbiologic efficacy and safety
data regarding the optimal use of antipseudomonal therapy in young children with CF, and the
long-term follow-up of this unique cohort of children will supply important data on the effect
of Pa infection on subsequent health status, and the linked serum and DNA banks will
contribute valuable information on surrogate markers and genetic modifiers of early CF lung
disease.
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EPIC study diagram and overlap between the clinical trial and the observational study.
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Randomization assignment of participants enrolling in the clinical trial component of EPIC.
*Patients with culture positive for Pa at the end of 28 days of inhaled therapy will receive a
second 28-day treatment course for the first cycle only.
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EPIC clinical trial enrollment by month. Solid line indicates actual enrollment, dotted line
indicates projected enrollment.
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Table 1
EPIC-OBS Data and sample collection schedule
Enrollment Quarterly Encounter Annually Hospitalization or
IV Antibiotic
EPIC-OBS enrollment form X
Registry clinical encounter form X
EPIC-OBS clinical encounter forma X
Registry year-end survey X
EPIC-OBS year-end surveyb X X
Registry hospitalization/IV history X
Results of respiratory culture (local site lab)c X
Results of outpatient complete blood countd X
Serum for serology and banking X
Respiratory specimen sent to Core Microbiology Labe X
a
The EPIC-OBS clinical encounter form collects information about the following characteristics: use of oral and inhaled antibiotics since the previous
visit, presence of crackles or wheezes on chest auscultation, cough frequency, cold symptoms, physical activity level, and activity limitations due to
respiratory symptoms;
b
The EPIC-OBS year-end survey collects information about the following exposures: influenza and pneumococcal vaccines; environmental tobacco
smoke; wood-burning stoves; hot tubs; swimming pools; attendance at social events with individuals who have CF; playing with other children who have
CF; other household members with CF; daycare attendance; Synagis® prophylaxis; breast-feeding; mother’s education; and annual household income;
c
Culture results from routine clinical cultures performed at the local site laboratory are recorded in the Registry clinical encounter forms;
d
Result of outpatient complete blood counts are recorded on the EPIC-OBS clinical encounter form;
e
After the first isolation of Pa from a respiratory culture at the local site laboratory, annual respiratory specimens (OP swab or sputum) are shipped to and
processed at the Cystic Fibrosis Foundation Therapeutics Development (TDN) Core Microbiology Laboratory. If possible, initial Pa isolates from the
local site laboratory will also be shipped to the TDN Core Microbiology Laboratory.
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Table 2
Estimated annual number of eligible patients among 60 U.S. CF centers in 2000 based on the CFF National
Patient Registry
Age Group No. previously Pa negative No. with first Pa positive oropharyngeal
culture
% Annual rate of first Pa positive
oropharyngeal culture
1–3 569 104 18.4
4–6 573 77 13.4
7–9 482 62 12.8
10–13 485 71 14.7
Total 2,109 314 14.9
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Table 3
Definition of pulmonary exacerbation – minimal criteria for treatment with anti-pseudomonal antibiotics
The presence of a pulmonary exacerbation is established by the following: One of the major criteria alone or two of the minor signs/symptoms and
fulfillment of symptom duration.
Major Criteria: (One finding alone establishes the presence of a pulmonary exacerbation)
1 Decrease in FEV1 of ≥10% from best baseline within past 6 months, unresponsive to albuterol (in participants able to reproducibly perform
spirometry)
2 Oxygen saturation <90% on room air or ≥5% decline from previous baseline
3 New lobar infiltrate(s) or atelectasi(e)s on chest radiograph
4 Hemoptysis (more than streaks on more than one occasion in past week)
Minor Signs/Symptoms: (Two minor signs/symptoms are required with duration criteria in the absence of major criteria)
1 Increased work of breathing or respiratory rate
2 New or increased adventitial sounds on lung exam
3 Weight loss ≥5% of body weight or decrease across 1 major percentile in weight percentile for age in past 6 months
4 Increased cough
5 Decreased exercise tolerance or level of activity
6 Increased chest congestion or change in sputum
Signs/Symptom Duration: (Required with two minor signs/symptoms in absence of major criteria)
1 Duration of sign/symptoms ≥5 days or significant symptom severity
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